TY  - JOUR
AU  - Camargo, Luana Cristina
AU  - Gering, Ian
AU  - Mastalipour, Mohammadamin
AU  - Kraemer-Schulien, Victoria
AU  - Bujnicki, Tuyen
AU  - Willbold, Dieter
AU  - Coronado, Mônika A.
AU  - Eberle, Raphael J.
TI  - A Snake Venom Peptide and Its Derivatives Prevent Aβ 42 Aggregation and Eliminate Toxic Aβ 42 Aggregates In Vitro
JO  - ACS chemical neuroscience
VL  - 15
IS  - 14
SN  - 1948-7193
CY  - Washington, DC
PB  - ACS Publ.
M1  - FZJ-2024-04954
SP  - 2600 - 2611
PY  - 2024
AB  - Over a century has passed since Alois Alzheimer first described Alzheimer's disease (AD), and since then, researchers have made significant strides in understanding its pathology. One key feature of AD is the presence of amyloid-β (Aβ) peptides, which form amyloid plaques, and therefore, it is a primary target for treatment studies. Naturally occurring peptides have garnered attention for their potential pharmacological benefits, particularly in the central nervous system. In this study, nine peptide derivatives of Crotamine, a polypeptide from Crotalus durissus terrificus Rattlesnake venom, as well as one d-enantiomer, were evaluated for their ability to modulate Aβ42 aggregation through various assays such as ThT, QIAD, SPR, and sFIDA. All tested peptides were able to decrease Aβ42 aggregation and eliminate Aβ42 aggregates. Additionally, all of the peptides showed an affinity for Aβ42. This study is the first to describe the potential of crotamine derivative peptides against Aβ42 aggregation and to identify a promising d-peptide that could be used as an effective pharmacological tool against AD in the future.
LB  - PUB:(DE-HGF)16
C6  - 38957957
UR  - <Go to ISI:>//WOS:001263163500001
DO  - DOI:10.1021/acschemneuro.4c00089
UR  - https://juser.fz-juelich.de/record/1029094
ER  -